KNSA / Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Rachel Frank - Associate more_horizontal

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. more_horizontal

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. more_horizontal

Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa's dedication to targeting challenging autoimmune and i more_horizontal

HAMILTON, Bermuda, July 18, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call more_horizontal

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Inves more_horizontal

HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call a more_horizontal

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, th more_horizontal